Research Development

Centron, Tsinghua University Ink R&D Pact on Dispensing Tech

Wuxi – September 19, 2026 -- Centron signed an industry-academia-research cooperation agreement with Professor Zhang Xiangyu's team from the Department of Mechanical Engineering at Tsinghua University, targeting process-consistency challenges in adhesive dispensing for manufacturing lines.

Agreement signed at Xishan Technology Transfer Conference in Wuxi

The deal was formalized on Sept. 15, 2026, during the 2026 Xishan Technology Transfer Conference, under the Xishan-Tsinghua industry-academia collaboration program. The framework operates on a model where enterprises raise production-floor questions, universities apply research-based methods, and market application tests the results.

CND Life Sciences Opens Scottsdale Innovation Lab for Neurodiagnostics R&D

Scottsdale, Ariz. – September 19, 2026 -- CND Life Sciences, Inc. has opened a new Innovation Laboratory in Scottsdale, Arizona, expanding its research and product-development capacity for neurodegenerative disease diagnostics. The facility was inaugurated with a ribbon-cutting ceremony attended by employees, community members, and key stakeholders, and operations are set to begin next week.

New facility separates R&D from clinical testing operations

The Innovation Laboratory operates independently from CND's existing CLIA-certified, CAP-accredited, and CLEP-permitted clinical laboratory, which processes the company's Syn-One Test. The new space is dedicated to assay development, biomarker research, technology evaluation, and translational research programs, allowing the company to pursue early-stage science without disrupting clinical throughput.

BioMarin Adds Bristol Myers Squibb Research Chief Robert Plenge to Board

San Rafael, Calif. – September 17, 2026 -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has appointed Robert Plenge, M.D., Ph.D., to its Board of Directors, effective September 10, 2026.

Plenge brings nine-site global research oversight from Bristol Myers Squibb

Dr. Plenge currently serves as Executive Vice President, Chief Research Officer and Head of Research at Bristol Myers Squibb, directing scientific operations across nine research sites worldwide. He joined the company in November 2019 through its acquisition of Celgene Corp., where he had led the immunology and inflammation portfolio in research and early development.